Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hematopoietic Stem Cell Transplantation | 57 | 2024 | 5667 | 3.670 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 11 | 2023 | 269 | 3.620 |
Why?
|
Graft vs Host Disease | 41 | 2024 | 3026 | 3.400 |
Why?
|
Immunotherapy, Adoptive | 19 | 2024 | 1468 | 2.030 |
Why?
|
Transplantation, Homologous | 23 | 2024 | 4822 | 1.470 |
Why?
|
Transplantation Conditioning | 18 | 2024 | 1591 | 1.330 |
Why?
|
Hematologic Neoplasms | 16 | 2024 | 1895 | 1.120 |
Why?
|
Cord Blood Stem Cell Transplantation | 4 | 2019 | 305 | 1.100 |
Why?
|
Epstein-Barr Virus Infections | 6 | 2024 | 614 | 1.060 |
Why?
|
Lymphoproliferative Disorders | 3 | 2024 | 530 | 1.020 |
Why?
|
Herpesvirus 4, Human | 9 | 2024 | 1076 | 0.920 |
Why?
|
Myelodysplastic Syndromes | 6 | 2024 | 1393 | 0.850 |
Why?
|
Antigens, CD34 | 3 | 2024 | 655 | 0.850 |
Why?
|
NK Cell Lectin-Like Receptor Subfamily K | 2 | 2018 | 95 | 0.760 |
Why?
|
T-Lymphocytes | 15 | 2024 | 10203 | 0.720 |
Why?
|
Leukemia, Myeloid, Acute | 10 | 2024 | 3609 | 0.710 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 2 | 2022 | 307 | 0.660 |
Why?
|
Treatment Failure | 3 | 2024 | 2643 | 0.660 |
Why?
|
Interleukin-2 | 8 | 2022 | 1891 | 0.650 |
Why?
|
Myeloablative Agonists | 4 | 2018 | 209 | 0.650 |
Why?
|
Macrophage Activation Syndrome | 1 | 2019 | 124 | 0.620 |
Why?
|
Graft vs Tumor Effect | 1 | 2016 | 68 | 0.530 |
Why?
|
Transplants | 1 | 2018 | 206 | 0.530 |
Why?
|
Graft vs Leukemia Effect | 2 | 2020 | 121 | 0.510 |
Why?
|
Fetal Blood | 3 | 2016 | 1347 | 0.500 |
Why?
|
Blood Specimen Collection | 1 | 2016 | 238 | 0.500 |
Why?
|
Lymphocyte Transfusion | 1 | 2016 | 232 | 0.490 |
Why?
|
Neurotoxicity Syndromes | 4 | 2023 | 301 | 0.490 |
Why?
|
Immunologic Deficiency Syndromes | 1 | 2018 | 548 | 0.470 |
Why?
|
Hepatic Veno-Occlusive Disease | 3 | 2022 | 220 | 0.450 |
Why?
|
Receptors, Antigen, T-Cell | 8 | 2024 | 2549 | 0.450 |
Why?
|
T-Lymphocytes, Regulatory | 9 | 2022 | 3092 | 0.440 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2018 | 686 | 0.440 |
Why?
|
Antilymphocyte Serum | 1 | 2015 | 491 | 0.430 |
Why?
|
Viral Matrix Proteins | 1 | 2014 | 193 | 0.410 |
Why?
|
Hematopoietic Stem Cells | 5 | 2022 | 3388 | 0.410 |
Why?
|
Lymphoma | 4 | 2020 | 1898 | 0.410 |
Why?
|
Cytokines | 6 | 2024 | 7386 | 0.400 |
Why?
|
Recurrence | 16 | 2024 | 8456 | 0.390 |
Why?
|
Antigens, CD19 | 4 | 2022 | 424 | 0.360 |
Why?
|
Tissue Donors | 5 | 2022 | 2334 | 0.360 |
Why?
|
Gastrointestinal Diseases | 1 | 2018 | 1201 | 0.340 |
Why?
|
Humans | 118 | 2024 | 761098 | 0.340 |
Why?
|
Organ Transplantation | 3 | 2024 | 1164 | 0.330 |
Why?
|
Pyrazoles | 2 | 2019 | 2010 | 0.330 |
Why?
|
Adult | 61 | 2024 | 221083 | 0.330 |
Why?
|
Blood Component Removal | 2 | 2022 | 132 | 0.330 |
Why?
|
Virus Diseases | 1 | 2015 | 716 | 0.320 |
Why?
|
Antiphospholipid Syndrome | 1 | 2010 | 165 | 0.300 |
Why?
|
Epstein-Barr Virus Nuclear Antigens | 3 | 2003 | 158 | 0.300 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2020 | 1372 | 0.290 |
Why?
|
Ferritins | 3 | 2022 | 597 | 0.290 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 3 | 2022 | 1405 | 0.280 |
Why?
|
B-Lymphocytes | 5 | 2024 | 4744 | 0.280 |
Why?
|
CD4-Positive T-Lymphocytes | 7 | 2020 | 4372 | 0.280 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2014 | 1782 | 0.270 |
Why?
|
Steroids | 6 | 2023 | 929 | 0.270 |
Why?
|
Aged | 42 | 2024 | 169266 | 0.260 |
Why?
|
Middle Aged | 48 | 2024 | 220835 | 0.250 |
Why?
|
Multiple Myeloma | 2 | 2023 | 5145 | 0.240 |
Why?
|
Cyclophosphamide | 6 | 2023 | 2219 | 0.230 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 3 | 2021 | 1640 | 0.230 |
Why?
|
Killer Cells, Natural | 6 | 2022 | 2194 | 0.230 |
Why?
|
CD8-Positive T-Lymphocytes | 9 | 2024 | 4574 | 0.230 |
Why?
|
Dioxygenases | 3 | 2021 | 345 | 0.230 |
Why?
|
Transplantation Chimera | 3 | 2015 | 594 | 0.230 |
Why?
|
Hematopoietic Stem Cell Mobilization | 3 | 2022 | 225 | 0.220 |
Why?
|
Male | 50 | 2024 | 360675 | 0.220 |
Why?
|
Young Adult | 20 | 2024 | 59199 | 0.210 |
Why?
|
Activated-Leukocyte Cell Adhesion Molecule | 1 | 2022 | 21 | 0.210 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2003 | 1351 | 0.210 |
Why?
|
Perforin | 2 | 2018 | 166 | 0.210 |
Why?
|
Female | 50 | 2024 | 392458 | 0.200 |
Why?
|
Transplantation, Autologous | 4 | 2021 | 2112 | 0.200 |
Why?
|
Ligands | 2 | 2018 | 3266 | 0.190 |
Why?
|
Autoantibodies | 1 | 2010 | 2117 | 0.190 |
Why?
|
Anemia, Sickle Cell | 2 | 2020 | 1063 | 0.190 |
Why?
|
Opportunistic Infections | 1 | 2023 | 376 | 0.180 |
Why?
|
Clone Cells | 4 | 2020 | 1667 | 0.180 |
Why?
|
Natural Killer T-Cells | 1 | 2024 | 322 | 0.180 |
Why?
|
Survival Rate | 9 | 2022 | 12727 | 0.170 |
Why?
|
gamma-Globins | 1 | 2020 | 105 | 0.170 |
Why?
|
Janus Kinase 1 | 1 | 2019 | 107 | 0.160 |
Why?
|
Certification | 1 | 2023 | 418 | 0.160 |
Why?
|
BK Virus | 1 | 2020 | 120 | 0.160 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.160 |
Why?
|
Photopheresis | 1 | 2019 | 35 | 0.160 |
Why?
|
Disease-Free Survival | 6 | 2018 | 6817 | 0.160 |
Why?
|
Bone Marrow Transplantation | 2 | 2023 | 2692 | 0.160 |
Why?
|
Retrospective Studies | 21 | 2024 | 80673 | 0.150 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2019 | 299 | 0.150 |
Why?
|
Biological Products | 3 | 2022 | 913 | 0.150 |
Why?
|
Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 263 | 0.150 |
Why?
|
Fetal Hemoglobin | 1 | 2020 | 345 | 0.150 |
Why?
|
Lymphocyte Activation | 4 | 2022 | 5478 | 0.150 |
Why?
|
Chronic Disease | 11 | 2023 | 9317 | 0.150 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2021 | 651 | 0.150 |
Why?
|
Vidarabine | 4 | 2021 | 336 | 0.140 |
Why?
|
Heterocyclic Compounds | 1 | 2018 | 245 | 0.140 |
Why?
|
Cytomegalovirus Infections | 1 | 2023 | 828 | 0.140 |
Why?
|
Sulfonamides | 2 | 2024 | 1977 | 0.140 |
Why?
|
Treatment Outcome | 12 | 2024 | 64670 | 0.130 |
Why?
|
Hematologic Diseases | 2 | 2018 | 496 | 0.130 |
Why?
|
Clinical Trials as Topic | 4 | 2021 | 8000 | 0.130 |
Why?
|
Janus Kinase 2 | 1 | 2019 | 559 | 0.130 |
Why?
|
Tacrolimus | 4 | 2023 | 735 | 0.130 |
Why?
|
Cryopreservation | 2 | 2021 | 728 | 0.130 |
Why?
|
Down-Regulation | 2 | 2020 | 2915 | 0.130 |
Why?
|
Tandem Repeat Sequences | 1 | 2016 | 180 | 0.130 |
Why?
|
Stem Cell Factor | 1 | 2015 | 195 | 0.120 |
Why?
|
Interleukin-7 | 1 | 2015 | 143 | 0.120 |
Why?
|
Mediastinal Neoplasms | 1 | 2017 | 401 | 0.120 |
Why?
|
Kidney | 2 | 2010 | 7034 | 0.120 |
Why?
|
Cell Division | 2 | 2004 | 4451 | 0.120 |
Why?
|
T-Lymphocyte Subsets | 3 | 2016 | 1803 | 0.120 |
Why?
|
Lymphocyte Depletion | 1 | 2016 | 602 | 0.120 |
Why?
|
Nitriles | 1 | 2019 | 971 | 0.110 |
Why?
|
Niacinamide | 1 | 2016 | 413 | 0.110 |
Why?
|
Brain Edema | 1 | 2018 | 604 | 0.110 |
Why?
|
HLA Antigens | 1 | 2019 | 1331 | 0.110 |
Why?
|
Busulfan | 3 | 2021 | 258 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8519 | 0.110 |
Why?
|
Amyotrophic Lateral Sclerosis | 1 | 2024 | 1462 | 0.110 |
Why?
|
Antigens, Surface | 1 | 2017 | 1607 | 0.110 |
Why?
|
Adolescent | 13 | 2024 | 88271 | 0.110 |
Why?
|
Receptors, Interleukin-2 | 1 | 2015 | 564 | 0.110 |
Why?
|
Phenylurea Compounds | 1 | 2016 | 529 | 0.110 |
Why?
|
Remission Induction | 2 | 2016 | 2392 | 0.110 |
Why?
|
Consensus | 1 | 2023 | 3133 | 0.110 |
Why?
|
Drug Resistance | 1 | 2019 | 1594 | 0.110 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2016 | 495 | 0.100 |
Why?
|
DNA-Binding Proteins | 4 | 2021 | 9566 | 0.100 |
Why?
|
Lymphocyte Count | 3 | 2019 | 781 | 0.100 |
Why?
|
Histocompatibility Testing | 3 | 2015 | 716 | 0.100 |
Why?
|
Models, Immunological | 1 | 2014 | 515 | 0.100 |
Why?
|
Repressor Proteins | 2 | 2020 | 2974 | 0.100 |
Why?
|
Child | 8 | 2023 | 80134 | 0.100 |
Why?
|
RNA Interference | 1 | 2020 | 2816 | 0.100 |
Why?
|
Gene Deletion | 1 | 2019 | 2656 | 0.100 |
Why?
|
Incidence | 4 | 2023 | 21357 | 0.100 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2020 | 1549 | 0.090 |
Why?
|
Neoplasm, Residual | 1 | 2016 | 1008 | 0.090 |
Why?
|
Saccharomyces cerevisiae | 1 | 2022 | 2667 | 0.090 |
Why?
|
Mutation | 6 | 2021 | 30006 | 0.090 |
Why?
|
DNA, Neoplasm | 1 | 2016 | 1743 | 0.090 |
Why?
|
Cell Separation | 1 | 2016 | 1718 | 0.090 |
Why?
|
Cell Proliferation | 4 | 2019 | 10421 | 0.090 |
Why?
|
Lymphoma, B-Cell | 1 | 2017 | 938 | 0.090 |
Why?
|
Receptors, IgE | 2 | 2003 | 375 | 0.090 |
Why?
|
Acute Kidney Injury | 1 | 2023 | 1923 | 0.090 |
Why?
|
Prognosis | 6 | 2022 | 29672 | 0.090 |
Why?
|
Cytomegalovirus | 1 | 2015 | 749 | 0.090 |
Why?
|
Antineoplastic Agents, Alkylating | 1 | 2014 | 617 | 0.090 |
Why?
|
Phagocytosis | 2 | 2015 | 1525 | 0.090 |
Why?
|
Stilbenes | 1 | 2011 | 155 | 0.090 |
Why?
|
T-Lymphocytes, Helper-Inducer | 1 | 2016 | 976 | 0.090 |
Why?
|
Herpesvirus 8, Human | 2 | 2004 | 255 | 0.090 |
Why?
|
Boronic Acids | 1 | 2014 | 915 | 0.090 |
Why?
|
Neoplasms | 3 | 2024 | 22125 | 0.080 |
Why?
|
Alleles | 4 | 2024 | 6857 | 0.080 |
Why?
|
Hematopoiesis | 2 | 2017 | 2046 | 0.080 |
Why?
|
Prednisone | 1 | 2014 | 1565 | 0.080 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2011 | 4340 | 0.080 |
Why?
|
Plasmapheresis | 1 | 2010 | 207 | 0.080 |
Why?
|
United States | 8 | 2024 | 72337 | 0.080 |
Why?
|
Stem Cell Transplantation | 1 | 2017 | 1600 | 0.080 |
Why?
|
Neoplasm Proteins | 1 | 2021 | 3594 | 0.080 |
Why?
|
Hodgkin Disease | 1 | 2017 | 1378 | 0.080 |
Why?
|
Leukocytes, Mononuclear | 1 | 2016 | 1837 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1051 | 0.080 |
Why?
|
Glioblastoma | 1 | 2024 | 3481 | 0.080 |
Why?
|
Phenotype | 2 | 2018 | 16572 | 0.080 |
Why?
|
Epitopes | 1 | 2015 | 2503 | 0.080 |
Why?
|
Cells, Cultured | 4 | 2016 | 18926 | 0.080 |
Why?
|
Pyrazines | 1 | 2014 | 1202 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 2021 | 0.080 |
Why?
|
Whole-Body Irradiation | 2 | 2019 | 432 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2813 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2019 | 15915 | 0.070 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5662 | 0.070 |
Why?
|
Erythropoiesis | 1 | 2011 | 683 | 0.070 |
Why?
|
Erythrocytes | 1 | 2016 | 2413 | 0.070 |
Why?
|
Pyrimidines | 1 | 2019 | 3026 | 0.070 |
Why?
|
Survival Analysis | 5 | 2018 | 10083 | 0.070 |
Why?
|
Age Factors | 3 | 2024 | 18385 | 0.070 |
Why?
|
Immunotherapy | 2 | 2019 | 4642 | 0.070 |
Why?
|
Fas Ligand Protein | 2 | 2003 | 216 | 0.070 |
Why?
|
Cell Line, Tumor | 4 | 2018 | 16947 | 0.070 |
Why?
|
Lymphocytes | 2 | 2024 | 2603 | 0.060 |
Why?
|
Melanoma | 1 | 2024 | 5694 | 0.060 |
Why?
|
Neutropenia | 1 | 2010 | 885 | 0.060 |
Why?
|
Antigens, CD7 | 1 | 2024 | 29 | 0.060 |
Why?
|
Disease Management | 1 | 2015 | 2508 | 0.060 |
Why?
|
Polyglutamic Acid | 2 | 1994 | 47 | 0.060 |
Why?
|
Trans-Activators | 2 | 2007 | 2846 | 0.060 |
Why?
|
Neutrophils | 1 | 2016 | 3763 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2011 | 1624 | 0.060 |
Why?
|
Venous Thromboembolism | 1 | 2017 | 1868 | 0.060 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2003 | 130 | 0.050 |
Why?
|
Aged, 80 and over | 5 | 2020 | 58946 | 0.050 |
Why?
|
Immunoglobulin A | 1 | 2007 | 978 | 0.050 |
Why?
|
Societies | 1 | 2023 | 107 | 0.050 |
Why?
|
Antigens, CD | 2 | 2024 | 4008 | 0.050 |
Why?
|
RNA, Transfer, Lys | 1 | 2002 | 8 | 0.050 |
Why?
|
NF-kappa B | 1 | 2011 | 2475 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2007 | 989 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3094 | 0.050 |
Why?
|
Fetal Proteins | 1 | 2022 | 98 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3216 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2018 | 1867 | 0.050 |
Why?
|
Cell Transformation, Viral | 1 | 2003 | 526 | 0.050 |
Why?
|
Azacitidine | 1 | 2024 | 336 | 0.050 |
Why?
|
Immunologic Memory | 2 | 2016 | 1361 | 0.050 |
Why?
|
Serology | 1 | 2001 | 7 | 0.050 |
Why?
|
HIV Reverse Transcriptase | 1 | 2002 | 212 | 0.050 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2270 | 0.050 |
Why?
|
Graft Rejection | 1 | 2014 | 4479 | 0.050 |
Why?
|
Cell Adhesion Molecules, Neuronal | 1 | 2022 | 263 | 0.050 |
Why?
|
Anemia | 1 | 2010 | 1504 | 0.050 |
Why?
|
Polydeoxyribonucleotides | 1 | 2022 | 136 | 0.050 |
Why?
|
Antigens, Differentiation, T-Lymphocyte | 1 | 2022 | 897 | 0.040 |
Why?
|
Immunomodulation | 1 | 2024 | 549 | 0.040 |
Why?
|
Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Burkitt Lymphoma | 1 | 2002 | 335 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6482 | 0.040 |
Why?
|
Signal Transduction | 3 | 2019 | 23415 | 0.040 |
Why?
|
Methotrexate | 2 | 2018 | 1717 | 0.040 |
Why?
|
Toll-Like Receptor 9 | 1 | 2020 | 193 | 0.040 |
Why?
|
Viral Proteins | 1 | 2007 | 1798 | 0.040 |
Why?
|
Histocompatibility Antigens Class II | 1 | 2003 | 1435 | 0.040 |
Why?
|
Cell Size | 1 | 2001 | 625 | 0.040 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 890 | 0.040 |
Why?
|
Leukemia, Myeloid | 1 | 2021 | 693 | 0.040 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2024 | 1089 | 0.040 |
Why?
|
Amino Acid Substitution | 2 | 2018 | 1737 | 0.040 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2000 | 433 | 0.040 |
Why?
|
Melphalan | 1 | 2019 | 420 | 0.040 |
Why?
|
Biopsy | 1 | 2010 | 6781 | 0.040 |
Why?
|
Risk Factors | 4 | 2020 | 74219 | 0.040 |
Why?
|
Mice, Mutant Strains | 1 | 2020 | 1750 | 0.040 |
Why?
|
Benzylamines | 1 | 2018 | 247 | 0.040 |
Why?
|
Acute Disease | 2 | 2020 | 7240 | 0.040 |
Why?
|
Immediate-Early Proteins | 1 | 2000 | 444 | 0.040 |
Why?
|
Cell Line | 4 | 2004 | 15542 | 0.040 |
Why?
|
Th1 Cells | 1 | 2002 | 1042 | 0.040 |
Why?
|
Coculture Techniques | 2 | 2016 | 1334 | 0.040 |
Why?
|
Maximum Tolerated Dose | 1 | 2019 | 883 | 0.030 |
Why?
|
Simian immunodeficiency virus | 1 | 2002 | 810 | 0.030 |
Why?
|
Time Factors | 4 | 2021 | 39953 | 0.030 |
Why?
|
Leukopenia | 1 | 2017 | 213 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2024 | 1984 | 0.030 |
Why?
|
Proto-Oncogene Proteins | 2 | 2020 | 4510 | 0.030 |
Why?
|
Lymphocyte Cooperation | 1 | 2016 | 112 | 0.030 |
Why?
|
Pilot Projects | 2 | 2020 | 8639 | 0.030 |
Why?
|
Antineoplastic Agents | 2 | 2016 | 13630 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2020 | 1602 | 0.030 |
Why?
|
Germ Cells | 1 | 2020 | 632 | 0.030 |
Why?
|
Workflow | 1 | 2021 | 850 | 0.030 |
Why?
|
STAT5 Transcription Factor | 1 | 2016 | 266 | 0.030 |
Why?
|
Follow-Up Studies | 4 | 2022 | 39121 | 0.030 |
Why?
|
Sequence Analysis, DNA | 2 | 2017 | 4739 | 0.030 |
Why?
|
Membrane Glycoproteins | 2 | 2003 | 3696 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 1661 | 0.030 |
Why?
|
Outpatients | 1 | 2023 | 1596 | 0.030 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9278 | 0.030 |
Why?
|
Antibodies, Viral | 1 | 2007 | 3149 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 2 | 2015 | 17889 | 0.030 |
Why?
|
Animals | 5 | 2024 | 168083 | 0.030 |
Why?
|
Lymphopoiesis | 1 | 2016 | 133 | 0.030 |
Why?
|
Immunoprecipitation | 1 | 2017 | 873 | 0.030 |
Why?
|
Flow Cytometry | 2 | 2007 | 5870 | 0.030 |
Why?
|
Inflammation | 1 | 2015 | 10758 | 0.030 |
Why?
|
Graft Survival | 2 | 2017 | 3841 | 0.030 |
Why?
|
Algorithms | 1 | 2015 | 14023 | 0.030 |
Why?
|
Gastrointestinal Tract | 1 | 2020 | 834 | 0.030 |
Why?
|
Anticoagulants | 1 | 2010 | 4795 | 0.030 |
Why?
|
Platelet Count | 1 | 2017 | 782 | 0.030 |
Why?
|
Virus Replication | 1 | 2002 | 2426 | 0.030 |
Why?
|
Anti-Inflammatory Agents | 1 | 2024 | 1812 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2004 | 3210 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2018 | 1837 | 0.030 |
Why?
|
Chemoembolization, Therapeutic | 1 | 1994 | 128 | 0.030 |
Why?
|
Age of Onset | 1 | 2020 | 3307 | 0.030 |
Why?
|
Leukemia | 1 | 2021 | 1518 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 851 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10755 | 0.030 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2016 | 629 | 0.030 |
Why?
|
Antibody Formation | 1 | 2017 | 1391 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2011 | 5318 | 0.030 |
Why?
|
Dendritic Cells | 1 | 2003 | 2726 | 0.030 |
Why?
|
Plasma Cells | 1 | 2016 | 597 | 0.030 |
Why?
|
RNA | 1 | 2002 | 2708 | 0.020 |
Why?
|
Syndrome | 1 | 2018 | 3269 | 0.020 |
Why?
|
Death | 1 | 2016 | 675 | 0.020 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2021 | 2820 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 2024 | 9518 | 0.020 |
Why?
|
Cell Count | 1 | 2016 | 1831 | 0.020 |
Why?
|
Disease Progression | 2 | 2020 | 13506 | 0.020 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1790 | 0.020 |
Why?
|
Erythroid-Specific DNA-Binding Factors | 1 | 2011 | 195 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2020 | 3409 | 0.020 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1878 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2018 | 20981 | 0.020 |
Why?
|
Genetic Vectors | 1 | 2020 | 3388 | 0.020 |
Why?
|
Pandemics | 2 | 2021 | 8663 | 0.020 |
Why?
|
Genetic Markers | 1 | 2017 | 2599 | 0.020 |
Why?
|
Skin Diseases | 1 | 2019 | 1095 | 0.020 |
Why?
|
Erythroid Precursor Cells | 1 | 2011 | 212 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2017 | 2189 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2019 | 2307 | 0.020 |
Why?
|
Vaccination | 1 | 2022 | 3368 | 0.020 |
Why?
|
Antibodies | 1 | 2017 | 2415 | 0.020 |
Why?
|
Th17 Cells | 1 | 2016 | 794 | 0.020 |
Why?
|
Lung Diseases | 1 | 2019 | 1909 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2024 | 4240 | 0.020 |
Why?
|
Cisplatin | 1 | 1994 | 1651 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3821 | 0.020 |
Why?
|
DNA Mutational Analysis | 1 | 2017 | 4109 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4245 | 0.020 |
Why?
|
Prospective Studies | 3 | 2020 | 54419 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9324 | 0.020 |
Why?
|
Kinetics | 1 | 2015 | 6312 | 0.020 |
Why?
|
Cohort Studies | 3 | 2018 | 41486 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2016 | 2881 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2011 | 13382 | 0.020 |
Why?
|
Health Services Accessibility | 1 | 2024 | 5427 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12341 | 0.020 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2017 | 2914 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2011 | 1331 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22129 | 0.020 |
Why?
|
Antibodies, Monoclonal | 1 | 2022 | 9185 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2018 | 4189 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81324 | 0.020 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18217 | 0.020 |
Why?
|
HIV-1 | 1 | 2002 | 6851 | 0.010 |
Why?
|
Contactins | 1 | 2004 | 21 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2369 | 0.010 |
Why?
|
Genetic Variation | 1 | 2019 | 6565 | 0.010 |
Why?
|
Neural Cell Adhesion Molecules | 1 | 2004 | 122 | 0.010 |
Why?
|
Binding Sites | 2 | 2002 | 5993 | 0.010 |
Why?
|
Child, Preschool | 2 | 2021 | 42217 | 0.010 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2011 | 1605 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7567 | 0.010 |
Why?
|
Cytopathogenic Effect, Viral | 1 | 2002 | 151 | 0.010 |
Why?
|
HLA-DQ Antigens | 1 | 2002 | 190 | 0.010 |
Why?
|
Viral Core Proteins | 1 | 2002 | 158 | 0.010 |
Why?
|
Base Sequence | 2 | 2003 | 12404 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12058 | 0.010 |
Why?
|
Gene Products, gag | 1 | 2002 | 312 | 0.010 |
Why?
|
Models, Molecular | 1 | 2011 | 5413 | 0.010 |
Why?
|
Glycosylation | 1 | 2004 | 1095 | 0.010 |
Why?
|
Phosphonoacetic Acid | 1 | 2000 | 54 | 0.010 |
Why?
|
Contrast Media | 1 | 1994 | 5311 | 0.010 |
Why?
|
HLA-DR Antigens | 1 | 2002 | 606 | 0.010 |
Why?
|
Particle Size | 2 | 1994 | 1649 | 0.010 |
Why?
|
Nucleotides | 1 | 2002 | 452 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36164 | 0.010 |
Why?
|
Pyridines | 1 | 2011 | 2872 | 0.010 |
Why?
|
DNA Primers | 1 | 2003 | 2815 | 0.010 |
Why?
|
Deoxyribonucleases | 1 | 2000 | 209 | 0.010 |
Why?
|
Plasmids | 1 | 2004 | 2261 | 0.010 |
Why?
|
Nucleic Acid Conformation | 1 | 2002 | 896 | 0.010 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2002 | 822 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2004 | 4168 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 2002 | 1518 | 0.010 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2000 | 621 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 11732 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2011 | 5300 | 0.010 |
Why?
|
Risk Assessment | 1 | 2017 | 24013 | 0.010 |
Why?
|
Iopanoic Acid | 1 | 1994 | 20 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2004 | 6507 | 0.010 |
Why?
|
Capsules | 1 | 1994 | 191 | 0.010 |
Why?
|
DNA, Viral | 1 | 2000 | 2195 | 0.010 |
Why?
|
Estrone | 1 | 1994 | 234 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2000 | 6123 | 0.010 |
Why?
|
Enzymes | 1 | 1994 | 252 | 0.010 |
Why?
|
Escherichia coli | 1 | 2004 | 4205 | 0.010 |
Why?
|
Microspheres | 1 | 1994 | 783 | 0.010 |
Why?
|
Peptide Fragments | 1 | 2004 | 5103 | 0.010 |
Why?
|
Tissue Distribution | 1 | 1994 | 2262 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2002 | 17598 | 0.010 |
Why?
|
Drug Carriers | 1 | 1994 | 706 | 0.010 |
Why?
|
Rabbits | 1 | 1994 | 4749 | 0.000 |
Why?
|
Receptors, Estrogen | 1 | 1994 | 2208 | 0.000 |
Why?
|
RNA, Messenger | 1 | 2000 | 12743 | 0.000 |
Why?
|
Swine | 1 | 1994 | 5909 | 0.000 |
Why?
|
Liver | 1 | 1994 | 7513 | 0.000 |
Why?
|
Rats | 1 | 1994 | 23713 | 0.000 |
Why?
|
Tomography, X-Ray Computed | 1 | 1994 | 20600 | 0.000 |
Why?
|